SGLT2 inhibitors and GLP-1 receptor agonists: impact on mortality in diabetic patients with cardiovascular disease
Authors' conclusion
In patients with T2D and ASCVD, treatment with SGLT2-I and GLP-1RA, especially in combination, is associated with a substantial reduction in mortality. These findings highlight significant gaps in implementation and the urgent need to optimize use of evidence-based therapies in this high-risk population.
Study context
- Population
- Patients with T2D and established atherosclerotic CVD (atherosclerotic cardiovascular disease (ASCVD)), CARdiovascular and DIABetes (CARDIAB) cohortCARDIAB cohort
- Participants
- 138,397 patients
- Exposure
- SGLT2i and/or GLP-1 RA vs neither
- Outcome
- All-cause mortality
Methodological detailsreal-world
- Real-world
Main finding
As reported in the abstract
Each group vs neitherHazard ratio (95% CI)
SGLT2-I only
0.28(0.27–0.29)
GLP-1RA only
0.39(0.37–0.40)
Both
0.17(0.16–0.18)
Observational data: associations, not effects.
Further findings
Treatment patterns
Treatment patterns
- Female sex, older age, non-coronary ASCVD and no follow-up in specialized cardiology or diabetes clinics associated with lower treatment rates
Original publication
SGLT2 inhibitors and GLP-1 receptor agonists: impact on mortality in diabetic patients with cardiovascular disease. Cardiovasc Diabetol. Published 31 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →